Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

1153 details
Primary information
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameBioclate
CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc.
Brand DiscriptionBioclate is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary cell line. In culture the CHO cell line secretes recombinant antihemophilic factor into the cell culture medium. The rAHF is purified from the culture medium utilizin
Prescribed forTo treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia.
Chemical NameN.A.
FormulationBiocolate is available in single-dose bottles which contain nominally 250, 500 and 1000 International Units per bottle.When reconstituted with the appropriate volume of diluent, it contains the following stabilizers in maximum amounts: 12.5 mg/mL Albumin
Physcial AppearnceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder
Route of AdministrationIntravenous infusion
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.drugs.com/mtm/bioclate-recombinant.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)